- Race Oncology (RAC) executes a number of contracts to begin an observational cardioprotection breast cancer trial for its Zantrene product
- RCE appointed contract research organisations Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen and Research Services to support the trial
- The parties will support the observational stage of a phase I/IIb trial of Zantrene administered to breast cancer patients being treated with AC chemotherapy
- The aim of the study is to identify the rate and level of heart damage caused by AC chemo and observe the anti-cancer efficacy of the chemotherapy treatments
- RAC shares are up 3.02 per cent, trading at $2.05 at 2:51 pm AEDT
Race Oncology (RAC) has executed a number of contracts to begin an observational cardioprotection breast cancer trial for its Zantrene product.
The company has appointed contract research organisations Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen and Research Services to support the observational stage of a phase 1/2b clinical trial of Zantrene in breast cancer patients being treated with AC chemotherapy.
Race will pay Resolutum Global $422,389 for data management and biostatistics services, Beyond Drug Development $658,296 for clinical site management and monitoring, safety management reporting, and clinical study report development services, and NSW Regional Biospecimen & Research Services $206,928 for patient sample kit production, processing and sample storage services.
Up to 50 patients with breast cancer receiving AC chemotherapy will be recruited for the study. The patients will be monitored to identify the rate and level of heart damage caused by the standard-of-care treatment as well as its anti-cancer efficacy.
Race said data from this trial would help inform the design of a subsequent interventional trial it hoped would help patients avoid permanent heart damage caused by AC chemo treatments while at the same time improving anti-cancer outcomes.
The trial received human ethics approval at the start of February this year.
RAC shares were up 3.02 per cent and trading at $2.05 at 2:51 pm AEDT.